Statement of Changes in Beneficial Ownership (4)
June 07 2021 - 5:06PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
DRACHMAN JONATHAN G |
2. Issuer Name and Ticker or Trading Symbol
Neoleukin Therapeutics, Inc.
[
NLTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and CEO |
(Last)
(First)
(Middle)
C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/3/2021 |
(Street)
SEATTLE, WA 98102
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/3/2021 | | P | | 40000 | A | $9.4818 (1) | 2238686 | D | |
Common Stock | 6/4/2021 | | P | | 10000 | A | $9.6082 (2) | 2248686 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Represents the weighted average purchase price. The lowest price at which shares were purchased was $9.38 and the highest price at which shares were purchased was $9.51. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. |
(2) | Represents the weighted average purchase price. The lowest price at which shares were purchased was $9.56 and the highest price at which shares were purchased was $9.62. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
DRACHMAN JONATHAN G C/O NEOLEUKIN THERAPEUTICS, INC. 188 EAST BLAINE STREET, #450 SEATTLE, WA 98102 | X |
| President and CEO |
|
Signatures
|
/s/ Kris McGrew, as Attorney-in-Fact for Jonathan Drachman | | 6/7/2021 |
**Signature of Reporting Person | Date |
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Sep 2023 to Sep 2024